Loading organizations...
Nusirt has raised $6.6M across 2 funding rounds.
Key people at Nusirt.
Nusirt has raised $6.6M in total across 2 funding rounds.
NuSirt Biopharma develops therapeutic interventions by combining natural compounds with existing pharmaceuticals to activate the sirtuin pathway. This proprietary technology platform enhances cellular energy metabolism, targeting conditions associated with overnutrition and aging. The company improves metabolic health through a scientific approach, leveraging synergistic effects between compounds to modulate biological processes.
Founded in 2007 by Michael Zemel, PhD, who serves as Chief Scientific Officer and Co-Founder, NuSirt emerged from Dr. Zemel's distinguished background as a metabolic and nutritional researcher. His insight centered on the powerful potential of combining specific natural compounds, like the amino acid leucine, with established pharmaceutical agents to therapeutically modulate sirtuin activity.
NuSirt Biopharma’s pipeline addresses patients suffering from chronic metabolic disorders, including non-alcoholic fatty liver disease, obesity, and related cardiometabolic conditions. The company’s vision is to deliver innovative therapies that restore metabolic balance, combat widespread health challenges, and extend healthy lifespans. It provides foundational treatments for significant unmet medical needs.
Key people at Nusirt.
Nusirt has raised $6.6M in total across 2 funding rounds.
Nusirt's investors include Clay B. Thorp, Mountain Group Partners, TriStar Technology Ventures, Saturn Partners.
Nusirt has raised $6.6M across 2 funding rounds. Most recently, it raised $6.0M Series C in May 2015.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| May 13, 2015 | $6M Series C | Clay B. Thorp | Mountain Group Partners, TriStar Technology Ventures | Announced |
| May 1, 2012 | $600K Seed | — | Saturn Partners | Announced |
NuSirt Biopharma, Inc. is a biotechnology company specializing in developing innovative therapies for chronic metabolic diseases such as obesity and diabetes. It has created a unique technology platform that integrates natural compounds—specifically patented combinations of the essential amino acid leucine—with existing pharmaceutical agents to enhance their effectiveness and enable new therapeutic applications. NuSirt serves patients suffering from metabolic disorders by targeting underlying disease mechanisms, aiming to improve health outcomes and quality of life. The company has demonstrated growth momentum through multiple clinical studies validating its platform and has attracted significant funding, including a Series C round, reflecting investor confidence in its approach[1][2][3][4][5].
Founded in 2007 and headquartered in Nashville, Tennessee, NuSirt was established under the leadership of Michael Zemel and other key figures with expertise in metabolic disease and biotechnology. The idea emerged from research into how natural compounds could synergize with pharmaceuticals to address metabolic dysfunction more effectively. Early traction came from successful clinical trials and the development of a broad intellectual property portfolio, including at least thirteen issued patents worldwide, which protected their innovative platform. This foundation allowed NuSirt to evolve from a research-focused startup into a clinical-stage biotech company with a clear mission to combat metabolic diseases[5][2][4].
NuSirt is positioned at the intersection of biotechnology and metabolic health, riding the global trend of increasing prevalence of metabolic disorders driven by over-nutrition and sedentary lifestyles. The timing is critical as demand for innovative, effective treatments for obesity and diabetes is rising sharply. Market forces such as the growing acceptance of combination therapies and personalized medicine favor NuSirt’s platform approach. By enhancing existing pharmaceuticals with natural compounds, NuSirt contributes to a broader ecosystem shift toward safer, more effective metabolic disease management and supports the expanding market for GLP-1 companion products and related therapies[2][3][4].
Looking ahead, NuSirt is likely to continue advancing its clinical pipeline and expanding its product offerings, potentially entering new markets within metabolic and cardiometabolic diseases. Trends such as increased focus on precision nutrition, combination therapies, and the integration of natural compounds with pharmaceuticals will shape its trajectory. As metabolic diseases remain a global health priority, NuSirt’s innovative platform and validated clinical results position it to deepen its influence in biotech and healthcare. Its ongoing development of patented supplements and therapeutics could redefine treatment paradigms, making it a key player to watch in the metabolic disease space[2][5].
